A Clinical Trial to Evaluate the Safety and Efficacy of a Moisturizer Body Lotion and a Lip Moisturizer in Adults of Atopic Dermatitis.
Single Center, Open-label, Non-randomized Clinical Trial to Evaluate the Safety and Efficacy of a Moisturizer Body Lotion and the Safety and Perceived Efficacy of a Lip Moisturizer in Adults With Atopic Dermatitis Presenting Dermatological Lesion.
研究概览
研究类型
阶段
- 不适用
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Fitzpatrick Skin Type I to VI;
- Subjects with mild to moderate atopic dermatitis according to the SCORAD index (mild global score (up to 24) and moderate global score (between 25 to 50), presenting dermatological lesions at the initial study visit;
- Generally in good health based on medical history reported by the subject;
- Able to read, write, speak and understand Portuguese;
- Person who signed the Consent for Photograph Release and Informed Consent Form;
- Person who agrees to change their leave on body and lip moisturizers to the products of this study, and agrees to use them throughout the test period;
- Intends to complete the study and is willing and able to follow all study instructions.
Exclusion Criteria:
- Subject who attends the Study Site, on the inclusion visit, with leave on moisturizer applied on the instrumental and microbiome evaluation areas;
- Present the need for systemic treatments (as in severe atopic dermatitis cases) such as the use of oral corticosteroids or other types of systemic treatments, as assessed by the Study Physician;
- Perform topical antimicrobial therapies (such as sodium hypochlorite bath or use of topical antibiotics);
- Perform phototherapy;
- Use of antimicrobial / antibacterial / anti germ soaps or other cosmetic and hygiene products;
- Subject who has used other leave on moisturizers in the test areas (body, face and lip), with the exception of investigational products, and/or who has changed their hygiene products during the study;
- Has known allergies or adverse reactions to common topical skincare products;
- Present a skin condition that may influence the outcome of the study (e.g., psoriasis, active skin cancer, etc);
- Present skin lesions (e.g., ulcers, vesicles) or tattoos in the test areas, with the exception of lesions associated with mild or moderate atopic dermatitis;
- Has self-reported Type 1 or Type 2 diabetes or is taking insulin or another anti-diabetic medication;
- Is taking a medication that would mask an Adverse Event (AE) or confound the study results, including:
Immunosuppressive drugs within 2 months before Visit 1; Immunobiological drugs within 2 months before visit 1; Topical anti-inflammatory steroids (corticosteroids) within 15 days before the visit 1; Topical and systemic immunomodulators (such as Tacrolimus and Pimecrolimus) within 15 days before visit 1; Topical and systemic antibiotics 15 days before the visit 1; Non-steroidal anti-inflammatory drugs within 15 days before Visit 1 ; Antihistamines within 2 weeks before Visit 1;
- Is self-reported to be pregnant or planning to become pregnant during the study;
- Has a history of or a concurrent health/other condition/situation which may put the individual at significant risk, confound the study results, or interfere significantly with the individual's participation in the study;
- Participating simultaneously in another study;
- Is an employee/contractor or immediate family member of the PI, Study Site, or Sponsor;
- History of a confirmed Coronavirus disease (COVID-19) in the past 30 days;
- Contact with a person infected with COVID-19 within 14 days prior to inclusion;
- Any international travel within 14 days of inclusion, including members of the same family;
- Subjects with self-reported symptoms in the past 2 weeks: unexplained cough, shortness of breath / difficulty breathing, fatigue, body aches (headaches, muscle aches, stomach pains), conjunctivitis, loss of smell, loss of taste, lack of appetite, nausea, vomiting, diarrhea, palpitations, fever or pain / tightness in the chest; temperature ≥ 38.0 degrees Celsius/100.4 degrees Fahrenheit measured; use of fever reducers within the last 2 days of each onsite visit.
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Moisturizer Body Lotion and Lip Moisturizer Regimen
All participants will receive and use both products.
|
The body lotion product is a moisturizing formulation intended for topical use on the whole body and face.
It will be applied at least twice daily.
The lip product is a moisturizing formulation intended for topical use on the lips.
It will be applied at least twice daily.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from baseline of scores of erythema to 21 ± 2 days
大体时间:21 ± 2 days
|
At baseline and at 21 ± 2 days, the study physician will evaluate the whole body (including face) and the lips and score the identified erythemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify this skin reaction on the whole body (including face), and on the lips. The change from baseline will be evaluated to assess skin tolerance of both study products. |
21 ± 2 days
|
|
Change from baseline of the scores of peeling to 21 ± 2 days
大体时间:21 ± 2 days
|
At baseline and at 21 ± 2 days, the study physician will evaluate the whole body (including face) and the lips and score the identified peeling according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify this skin reaction on the whole body (including face), and on the lips. The change from baseline will be evaluated to assess skin tolerance of both study products. |
21 ± 2 days
|
|
Change from baseline of the scores of blistering to 21 ± 2 days
大体时间:21 ± 2 days
|
At baseline and at 21 ± 2 days, the study physician will evaluate the whole body (including face) and the lips and score the identified blistering according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify this skin reaction on the whole body (including face), and on the lips. The change from baseline will be evaluated to assess skin tolerance of both study products. |
21 ± 2 days
|
|
Change from baseline of the scores to edema to 21 ± 2 days
大体时间:21 ± 2 days
|
At baseline and at 21 ± 2 days, the study physician will evaluate the whole body (including face) and the lips and score the identified edema according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify this skin reaction on the whole body (including face), and on the lips. The change from baseline will be evaluated to assess skin tolerance of both study products. |
21 ± 2 days
|
|
21 ± 2 天内发生不良事件的参与者百分比
大体时间:长达 21 ± 2 天
|
将评估出现 AE、严重不良事件 (SAE)、导致停药的 AE 以及与皮肤反应相关的 AE 的参与者的百分比,以评估长达 21 ± 2 天的皮肤耐受性。
|
长达 21 ± 2 天
|
|
Change from baseline of scores of erythema to 5 ± 1 days
大体时间:5 ± 1 days
|
At baseline and at 5 ± 1 days, the study physician will evaluate the whole body (including face) and the lips and score the identified erythemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify this skin reaction on the whole body (including face), and on the lips. The change from baseline will be evaluated to assess skin tolerance of both study products. |
5 ± 1 days
|
|
Change from baseline of the scores of peeling to 5 ± 1 days
大体时间:5 ± 1 days
|
At baseline and at 5 ± 1 days, the study physician will evaluate the whole body (including face) and the lips and score the identified peeling according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify this skin reaction on the whole body (including face), and on the lips. The change from baseline will be evaluated to assess skin tolerance of both study products. |
5 ± 1 days
|
|
Change from baseline of the scores of blistering to 5 ± 1 days
大体时间:5 ± 1 days
|
At baseline and at 5 ± 1 days, the study physician will evaluate the whole body (including face) and the lips and score the identified blistering according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify this skin reaction on the whole body (including face), and on the lips. The change from baseline will be evaluated to assess skin tolerance of both study products. |
5 ± 1 days
|
|
Change from baseline of the scores of edema to 5 ± 1 days
大体时间:5 ± 1 days
|
At baseline and at 5 ± 1 days, the study physician will evaluate the whole body (including face) and the lips and score the identified edema according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify this skin reaction on the whole body (including face), and on the lips. The change from baseline will be evaluated to assess skin tolerance of both study products. |
5 ± 1 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
基于特应性皮炎评分指数 (SCORAD) 的特应性皮炎严重程度从基线到 21 ± 2 天的变化
大体时间:21±2天
|
将在基线和 21 ± 2 天时报告基于 SCORAD 指数的特应性皮炎 (AD) 严重程度。 该工具不仅涉及医学评估,还涉及受试者报告的主观症状评估。 该指数分为以下部分,并获得数字评分: 扩展(患有 AD 病变的区域);反应强度(红斑、水肿、渗出/结痂、擦伤、苔藓样变和皮肤干燥;以及主观症状(瘙痒和睡眠不足)。 为了评估这些参数,使用从 0 到 10 的等级。 最后,AD 的全局分类会自动归属于每个主题。 较低的总体分数意味着 AD 状况较不严重。 该评估将用于确定保湿身体乳在使用一段时间后对研究人群 AD 状况的影响。 |
21±2天
|
|
根据特应性皮炎评分指数 (SCORAD),特应性皮炎严重程度从基线到 5 ± 1 天的变化
大体时间:5±1天
|
将在基线和 5 ± 1 天时报告基于 SCORAD 指数的特应性皮炎 (AD) 严重程度。 该工具不仅涉及医学评估,还涉及受试者报告的主观症状评估。 该指数分为以下部分,并获得数字评分: 扩展(患有 AD 病变的区域);反应强度(红斑、水肿、渗出/结痂、擦伤、苔藓样变和皮肤干燥;以及主观症状(瘙痒和睡眠不足)。 为了评估这些参数,使用从 0 到 10 的等级。 最后,AD 的全局分类会自动归属于每个主题。 较低的总体分数意味着 AD 状况较不严重。 该评估将用于确定保湿身体乳在使用一段时间后对研究人群 AD 状况的影响。 |
5±1天
|
|
根据特应性皮炎评分指数 (SCORAD),特应性皮炎严重程度从 5 ± 1 天更改为 21 ± 2 天
大体时间:5±1天至21±2天
|
基于 SCORAD 指数的特应性皮炎 (AD) 严重程度将在 5 ± 1 天和 21 ± 2 天时报告。 该工具不仅涉及医学评估,还涉及受试者报告的主观症状评估。 该指数分为以下部分,并获得数字评分: 扩展(患有 AD 病变的区域);反应强度(红斑、水肿、渗出/结痂、擦伤、苔藓样变和皮肤干燥;以及主观症状(瘙痒和睡眠不足)。 为了评估这些参数,使用从 0 到 10 的等级。 最后,AD 的全局分类会自动归属于每个主题。 较低的总体分数意味着 AD 状况较不严重。 该评估将用于确定保湿身体乳在使用一段时间后对研究人群 AD 状况的影响。 |
5±1天至21±2天
|
|
Mean change from baseline to 21 ± 2 days in skin hydration level of areas with and without AD lesions
大体时间:21 ± 2 days
|
Skin hydration level of areas with and without AD lesions will be measured with corneometer, a recognized device that determine the water content of stratum corneum.
This measure will be used to determine the effect of the moisturizer body lotion on skin hydration of the study population after a period of use.
|
21 ± 2 days
|
|
Mean change from baseline to 5 ± 1 days in skin hydration level of areas with and without AD lesions
大体时间:5 ± 1 days
|
Skin hydration level of areas with and without AD lesions will be measured with corneometer, a recognized device that determine the water content of stratum corneum.
This measure will be used to determine the effect of the moisturizer body lotion on skin hydration of the study population after a period of use.
|
5 ± 1 days
|
|
Mean change from 5 ± 1 days to 21 ± 2 days in skin hydration level of areas with and without AD lesions
大体时间:5 ± 1 days to 21 ± 2 days
|
Skin hydration level of areas with and without AD lesions will be measured with corneometer, a recognized device that determine the water content of stratum corneum.
This measure will be used to determine the effect of the moisturizer body lotion on skin hydration of the study population after a period of use.
|
5 ± 1 days to 21 ± 2 days
|
|
Mean change from baseline to 21 ± 2 days in transepidermal water loss (TEWL) to assess skin barrier integrity of areas with and without AD lesions
大体时间:21 ± 2 days
|
Skin barrier integrity of areas with and without AD lesions will be evaluated using a recognized device that determine the transepidermal water loss.
Lower levels of TEWL may be related to a more integrate skin barrier.
This measure will be used to determine the effect of the moisturizer body lotion on skin barrier of the study population after a period of use.
|
21 ± 2 days
|
|
Mean change from baseline to 5 ± 1 days in transepidermal water loss (TEWL) to assess skin barrier integrity of areas with and without AD lesions
大体时间:5 ± 1 days
|
Skin barrier integrity of areas with and without AD lesions will be evaluated using a recognized device that determine the transepidermal water loss.
Lower levels of TEWL may be related to a more integrate skin barrier.
This measure will be used to determine the effect of the moisturizer body lotion on skin barrier of the study population after a period of use.
|
5 ± 1 days
|
|
Mean change from 5 ± 1 days to 21 ± 2 days in transepidermal water loss (TEWL) to assess skin barrier integrity of areas with and without AD lesions
大体时间:5 ± 1 days to 21 ± 2 days
|
Skin barrier integrity of areas with and without AD lesions will be evaluated using a recognized device that determine the transepidermal water loss.
Lower levels of TEWL may be related to a more integrate skin barrier.
This measure will be used to determine the effect of the moisturizer body lotion on skin barrier of the study population after a period of use.
|
5 ± 1 days to 21 ± 2 days
|
|
用于评估 AD 严重程度的以患者为导向的湿疹测量 (POEM) 总分从基线到 21 ± 2 天的平均变化
大体时间:21±2天
|
POEM 是一种简单、有效、易于解释且可重复的工具,用于评估 AD 和监测对 AD 参与者很重要的疾病方面。 该工具由参与者回答的一份调查问卷组成,其中包含与七种 AD 症状(皮肤瘙痒、睡眠障碍、皮肤出血、皮肤流泪/渗血、皮肤剥落、皮肤开裂、皮肤干燥/粗糙)相关的问题。 参与者必须回答每个问题,并使用以下选项指定每周出现该症状的次数:没有一天; 1至2天; 3至4天; 5至6天;每天。 然后每个响应都会收到以下分数之一: 0 = 无天; 1= 1-2 天; 2 = 3-4 天; 3 = 5-6 天 4= 每天。 最后根据7个项目的总分(0到28分)计算出总分。 分数越高,AD 状况越严重。 该测量将用于确定保湿身体乳在使用一段时间后对研究人群 AD 状况的影响。 |
21±2天
|
|
用于评估 AD 严重程度的以患者为导向的湿疹测量 (POEM) 总分从基线到 7 天的平均变化
大体时间:7天
|
POEM 是一种简单、有效、易于解释且可重复的工具,用于评估 AD 和监测对 AD 参与者很重要的疾病方面。 该工具由参与者回答的一份调查问卷组成,其中包含与七种 AD 症状(皮肤瘙痒、睡眠障碍、皮肤出血、皮肤流泪/渗血、皮肤剥落、皮肤开裂、皮肤干燥/粗糙)相关的问题。 参与者必须回答每个问题,并使用以下选项指定每周出现该症状的次数:没有一天; 1至2天; 3至4天; 5至6天;每天。 然后每个响应都会收到以下分数之一: 0 = 无天; 1= 1-2 天; 2 = 3-4 天; 3 = 5-6 天 4= 每天。 最后,将7个项目相加,计算出总分(评分从0到28)。 分数越高,AD 状况越严重。 该测量将用于确定保湿身体乳在使用一段时间后对研究人群 AD 状况的影响。 |
7天
|
|
用于评估 AD 严重程度的以患者为导向的湿疹测量 (POEM) 总分从基线到 14 天的平均变化
大体时间:14天
|
POEM 是一种简单、有效、易于解释且可重复的工具,用于评估 AD 和监测对 AD 参与者很重要的疾病方面。 该工具由参与者回答的一份调查问卷组成,其中包含与七种 AD 症状(皮肤瘙痒、睡眠障碍、皮肤出血、皮肤流泪/渗血、皮肤剥落、皮肤开裂、皮肤干燥/粗糙)相关的问题。 参与者必须回答每个问题,并使用以下选项指定每周出现该症状的次数:没有一天; 1至2天; 3至4天; 5至6天;每天。 然后每个响应都会收到以下分数之一: 0 = 无天; 1= 1-2 天; 2 = 3-4 天; 3 = 5-6 天 4= 每天。 最后,将7个项目相加,计算出总分(评分从0到28)。 分数越高,AD 状况越严重。 该测量将用于确定保湿身体乳在使用一段时间后对研究人群 AD 状况的影响。 |
14天
|
|
基线生活质量的感知功效
大体时间:基线
|
参与者将通过问卷调查对与生活质量相关的感知功效进行主观评估,其中的问题涉及 AD 对生活质量的影响。 参与者将使用以下定性量表回答每个问题: 受到很大影响;中度影响;受到一点影响;没有受到影响。 该问卷将用于在使用研究产品“保湿润肤露”之前评估 AD 对生活质量的影响。 每个问题的回答将以百分比形式提供。 |
基线
|
|
7 天后生活质量的感知功效
大体时间:7天
|
与生活质量相关的感知功效将由参与者通过问卷进行主观评估,其中包含与使用润肤乳 7 天后生活质量改善相关的问题。 参与者将使用以下定性标准回答每个问题: 非常有帮助;适度帮助;有点帮助;没有帮助。 该调查问卷将用于评估保湿身体乳在使用该产品一段时间后对生活质量的影响。 每个问题的回答将以百分比形式提供。 |
7天
|
|
14 天时生活质量的感知功效
大体时间:14天
|
与生活质量相关的感知功效将由参与者通过问卷进行主观评估,问卷中包含与使用润肤乳 14 天后生活质量改善相关的问题。 参与者将使用以下定性标准回答每个问题: 非常有帮助;适度帮助;有点帮助;没有帮助。 该调查问卷将用于评估保湿身体乳在使用该产品一段时间后对生活质量的影响。 每个问题的回答将以百分比形式提供。 |
14天
|
|
Perceived Efficacy in the quality of life at 21 ± 2 days
大体时间:21 ± 2 days
|
Perceived efficacy related to the quality of life will be subjectively evaluated by the participants through a questionnaire with questions related to the improvement in the quality of life after 21 ± 2 days of moisturizer body lotion usage. Participants will answer each question using the following qualitative scale: Helped very much; moderately helped; helped a little; did not helped. This questionnaire will be used to evaluate the impact of the moisturizer body lotion in the quality of life after periods of use of this product.The responses for each questions will be provided as percentages. |
21 ± 2 days
|
|
Perceived Efficacy of the moisturizer body lotion at 7 days
大体时间:7 days
|
Perceived efficacy related to the attributes of moisturizer body lotions will be subjectively evaluated by the participants through a questionnaire using the following qualitative scale: totally agree; agree; neither agree, nor disagree; disagree. The responses for each questions will be provided as percentages. |
7 days
|
|
Perceived Efficacy of the moisturizer body lotion at 14 days
大体时间:14 days
|
Perceived efficacy related to the attributes of moisturizer body lotions will be subjectively evaluated by the participants through a questionnaire using the following qualitative scale: totally agree; agree; neither agree, nor disagree; disagree. The responses for each questions will be provided as percentages. |
14 days
|
|
Perceived Efficacy of the moisturizer body lotion at 21 ± 2 days
大体时间:21 ± 2 days
|
Perceived efficacy related to the attributes of moisturizer body lotions will be subjectively evaluated by the participants through a questionnaire using the following qualitative scale: totally agree; agree; neither agree, nor disagree; disagree. The responses for each questions will be provided as percentages. |
21 ± 2 days
|
|
Perceived Efficacy of the lip moisturizer at 7 days
大体时间:7 days
|
Perceived efficacy related to the attributes of the lip moisturizer will be subjectively evaluated by the participants through a questionnaire using the following qualitative scale: totally agree; agree; neither agree, nor disagree; disagree. The answer option "Not applicable" can be used. The responses for each questions will be provided as percentages. |
7 days
|
|
Perceived Efficacy of the lip moisturizer at 21 ± 2 days
大体时间:21 ± 2 days
|
Perceived efficacy related to the attributes of the lip moisturizer will be subjectively evaluated by the participants through a questionnaire using the following qualitative scale: totally agree; agree; neither agree, nor disagree; disagree. The answer option "Not applicable" can be used. The responses for each questions will be provided as percentages. |
21 ± 2 days
|
|
Determination of types and quantity of bacteria (skin microbiome) of areas with and without AD lesions at baseline
大体时间:Baseline
|
Skin microbiome is a group of microorganisms, including bacteria, present on the skin surface and plays an important role in AD. To evaluate the type and number of bacteria present on the surface of areas with and without AD lesions, a sample will be collected on this areas using a swab. The evaluation will be done through metagenomics, a technique that allows the determination of the types and quantity of bacteria present in an specific area. This assessment will be used to determine the effect of the moisturizer body lotion on skin microbiome after a period of use. |
Baseline
|
|
Determination of types and quantity of bacteria (skin microbiome) of areas with and without AD lesions at 21 ± 2 days
大体时间:21 ± 2 days
|
Skin microbiome is a group of microorganisms, including bacteria, present on the skin surface and plays an important role in AD. To evaluate the type and number of bacteria present on the surface of areas with and without AD lesions, a sample will be collected on this areas using a swab. The evaluation will be done through metagenomics, a technique that allows the determination of the types and quantity of bacteria present in an specific area. This assessment will be used to determine the effect of the moisturizer body lotion on skin microbiome after a period of use. |
21 ± 2 days
|
|
Visual skin condition of areas with and without AD lesions at baseline captured photographically
大体时间:Baseline
|
Images of areas with and without AD lesions will be captured through a professional camera at baseline to visualize the skin condition of these areas before the use of moisturizer body lotion. No analysis is planned. These images will be used as a qualitative complement to the other results for moisturizer body lotion. |
Baseline
|
|
Visual skin condition of areas with and without AD lesions at 5 ± 1 days captured photographically
大体时间:5 ± 1 days
|
Images of areas with and without AD lesions will be captured through a professional camera at 5 ± 1 days to visualize the skin condition of these areas after the use of moisturizer body lotion. No analysis is planned. These images will be used as a qualitative complement to the other results for moisturizer body lotion. |
5 ± 1 days
|
|
Visual skin condition of areas with and without AD lesions at 21 ± 2 days captured photographically
大体时间:21 ± 2 days
|
Images of areas with and without AD lesions will be captured through a professional camera at 21 ± 2 days to visualize the skin condition of these areas after the use of moisturizer body lotion. No analysis is planned. These images will be used as a qualitative complement to the other results for moisturizer body lotion. |
21 ± 2 days
|
|
关于 21 ± 2 天使用保湿身体乳体验的感言
大体时间:21±2天
|
参与者将在研究结束时通过开放性问题提供有关保湿身体乳液体验的推荐。
目的是了解他们在研究期间使用该产品的意见和体验。
|
21±2天
|
合作者和调查者
出版物和有用的链接
一般刊物
- Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC; NISC Comparative Sequencing Program; Bouffard GG, Blakesley RW, Murray PR, Green ED, Turner ML, Segre JA. Topographical and temporal diversity of the human skin microbiome. Science. 2009 May 29;324(5931):1190-2. doi: 10.1126/science.1171700.
- Aoki V, Lorenzini D, Orfali RL, Zaniboni MC, Oliveira ZNP, Rivitti-Machado MC, Takaoka R, Weber MB, Cestari T, Gontijo B, Ramos AMC, Silva CMR, Cestari SDCP, Souto-Mayor S, Carneiro FR, Cerqueira AMM, Laczynski C, Pires MC. Consensus on the therapeutic management of atopic dermatitis - Brazilian Society of Dermatology. An Bras Dermatol. 2019 Apr;94(2 Suppl 1):67-75. doi: 10.1590/abd1806-4841.2019940210. Epub 2019 Jun 3.
- Gallo RL, Nakatsuji T. Microbial symbiosis with the innate immune defense system of the skin. J Invest Dermatol. 2011 Oct;131(10):1974-80. doi: 10.1038/jid.2011.182. Epub 2011 Jun 23.
- Stamatas GN, Capone K. New findings, and the impact of infant skin microbiota on product development. Cosmetics and Toiletries.
- Brazil. Conselho Nacional da Saúde. Resolution Nº 466, December 2012.
- Pan-American Health Organization. Good Clinical Practices: American Document. IV Pan-Americana Conference for Harmonization of Pharmaceutical Regulation, 2005.
- Blichmann CW, Serup J. Assessment of skin moisture. Measurement of electrical conductance, capacitance and transepidermal water loss. Acta Derm Venereol. 1988;68(4):284-90.
- Agner T, Serup J. Comparison of two electrical methods for measurement of skin hydration. An experimental study on an irritant patch test reaction.
- Brazil. Agência Nacional de Vigilância Sanitária (ANVISA). Guideline for Safety Assessment of Cosmetic Products. 2 edition, 2012.
- Brazil. Agência Nacional de Vigilância Sanitária (ANVISA). Resolution - RDC Nº 10, 03 March 2015.
研究记录日期
研究主要日期
学习开始 (预期的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- CCSSKA003745 (其他标识符:Johnson & Johnson Consumer Inc.)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.